Literature DB >> 9039272

Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.

K M Woods1, M V Nesterenko, S J Upton.   

Abstract

An in-situ ELISA was used as a primary screen to test the effects of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Over 40 of the compounds displayed some form of anticryptosporidial activity, and dose-response curves were generated for 40 of these. The in-situ ELISA makes a highly effective primary, pharmaceutical screen for C parvum, to be used prior to more detailed microscopical, toxicological or in-vivo assays.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9039272     DOI： 10.1080/00034983.1996.11813090

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN： 0003-4983


  22 in total

1.  Short-term exposure to membrane-active antibiotics inhibits Cryptosporidium parvum infection in cell culture.

Authors:  A Giacometti; O Cirioni; M S Del Prete; F Barchiesi; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP).

Authors:  Jason M Fritzler; Guan Zhu
Journal:  J Antimicrob Chemother       Date:  2011-12-13       Impact factor: 5.790

3.  CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages.

Authors:  M E Perkins; Y A Riojas; T W Wu; S M Le Blancq
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

4.  In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds.

Authors:  Klaus Teichmann; Maxime Kuliberda; Gerd Schatzmayr; Franz Hadacek; Anja Joachim
Journal:  Parasitol Res       Date:  2012-01-26       Impact factor: 2.289

5.  [(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: a new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha.

Authors:  W R Waters; B Frydman; L J Marton; A Valasinas; V K Reddy; J A Harp; M J Wannemuehler; N Yarlett
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum.

Authors:  M E Perkins; T W Wu; S M Le Blancq
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro.

Authors:  Xiaomin Cai; Keith M Woods; Steve J Upton; Guan Zhu
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

8.  The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum.

Authors:  J K Griffiths; C Theodos; M Paris; S Tzipori
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites.

Authors:  Dion A Kevin Ii; Damaris Af Meujo; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2009-02       Impact factor: 6.098

10.  Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models.

Authors:  C M Theodos; J K Griffiths; J D'Onfro; A Fairfield; S Tzipori
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.